Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization
Mid Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 70 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $336B.
The largest by market cap are Madrigal Pharmaceuticals (MDGL) at $9.8B, TG Therapeutics (TGTX) at $9.48B and Vaxcyte (PCVX) at $9.4B.
Among institutional investors, Twist Bioscience (TWST) drew the most net new fund positions in Q3 2026: 139 funds opened new positions, taking total fund holders up 92 (27%) quarter-over-quarter.
- Combined market cap: $336B across 70 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Madrigal Pharmaceuticals (MDGL), $9.8B market cap.
- Most net new fund positions in Q3 2026: Twist Bioscience (TWST), +92 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.